TheraRadar
← Back
Data updated: Jun 28, 2026

SWEDISH ORPHAN

Specialty
RespiratoryImmunologyCardiovascular Execution: Fair

SWEDISH ORPHAN is a specialty pharmaceutical company focused on Respiratory, Immunology, Cardiovascular.

1998
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules 1 Biologics

SWEDISH ORPHAN at a Glance

  • Fast trial execution (16 months median completion)

SWEDISH ORPHAN's Key Drugs

SWEDISH ORPHAN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SWEDISH ORPHAN's Recent FDA Approvals

New NDA/BLA approvals for SWEDISH ORPHAN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SWEDISH ORPHAN's Therapeutic Areas

SWEDISH ORPHAN's approved drugs and pipeline span 4 therapeutic areas, led by Respiratory and Immunology, across 1 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 35%
1 drugs Phase 2: 1
Immunology 35%
0 drugs Phase 3: 1 Phase 2: 2
Cardiovascular 26%
1 drugs
Rare Disease 4%
0 drugs Phase 1: 1

SWEDISH ORPHAN's Top Competitors

SWEDISH ORPHAN's closest competitors by therapeutic-area and drug-target overlap include Novartis, AstraZeneca, and Boehringer Ingelheim. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Cardiovascular, Respiratory, Immunology
AstraZeneca big-pharma
Respiratory, Cardiovascular, Immunology
Boehringer Ingelheim big-pharma
Respiratory, Cardiovascular, Immunology
LEDERLE big-pharma
Respiratory, Cardiovascular, Immunology
Gilead Sciences biotech
Immunology, Respiratory, Cardiovascular

SWEDISH ORPHAN Pipeline Snapshot

SWEDISH ORPHAN has 5 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 3 Phase 2 and 1 Phase 1.

1
Phase 3
3
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 6/12 completed
  • • Speed: 16 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges